» Articles » PMID: 35966097

Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019

Abstract

Background: To report the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories.

Methods: Using the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was reported in 1990 and 2019.

Results: Globally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers.

Conclusions: HFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPG-attributable cancers.

Citing Articles

Global burden of colorectal cancer attributable to metabolic risks from 1990 to 2021, with projections of mortality to 2035.

He M, Gu R, Huang X, Zhao A, Tian S, Zheng Y Int J Colorectal Dis. 2025; 40(1):46.

PMID: 39969585 PMC: 11839689. DOI: 10.1007/s00384-025-04817-w.


Global burden of colorectal cancer attributable to metabolic risks from 1990 to 2021, with predictions to 2046.

Zhang X, Xu Z, Shang L, Yang Q, Ye H, Liu H BMC Cancer. 2025; 25(1):228.

PMID: 39930395 PMC: 11809015. DOI: 10.1186/s12885-025-13643-w.


Trend and forecast analysis of the changing disease burden of pancreatic cancer attributable to high fasting glucose in China, 1990-2021.

Song L, Chen Z, Li Y, Ran L, Liao D, Zhang Y Front Oncol. 2024; 14:1471699.

PMID: 39493456 PMC: 11527594. DOI: 10.3389/fonc.2024.1471699.


Pancreatic cancer mortality trends attributable to high fasting blood sugar over the period 1990-2019 and projections up to 2040.

Wei Y, Qin Z, Liao X, Zhou X, Huang H, Lan C Front Endocrinol (Lausanne). 2024; 15:1302436.

PMID: 39036051 PMC: 11257875. DOI: 10.3389/fendo.2024.1302436.


Trends and projection of burden on lung cancer and risk factors in China from 1990 to 2060.

He B, Zhao X, Pu Y, Sun R, Gao X, Liu W Thorac Cancer. 2024; 15(22):1688-1704.

PMID: 38984468 PMC: 11293937. DOI: 10.1111/1759-7714.15332.


References
1.
Bullard T, Ji M, An R, Trinh L, Mackenzie M, Mullen S . A systematic review and meta-analysis of adherence to physical activity interventions among three chronic conditions: cancer, cardiovascular disease, and diabetes. BMC Public Health. 2019; 19(1):636. PMC: 6534868. DOI: 10.1186/s12889-019-6877-z. View

2.
Dendup T, Feng X, Clingan S, Astell-Burt T . Environmental Risk Factors for Developing Type 2 Diabetes Mellitus: A Systematic Review. Int J Environ Res Public Health. 2018; 15(1). PMC: 5800177. DOI: 10.3390/ijerph15010078. View

3.
Fang H, Yao B, Yan Y, Xu H, Liu Y, Tang H . Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Technol Ther. 2013; 15(11):914-22. PMC: 3817892. DOI: 10.1089/dia.2013.0131. View

4.
. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

5.
. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(9):627-37. DOI: 10.7326/0003-4819-149-9-200811040-00243. View